The extracellular matrix protein tenascin C (TnC) is expressed in a variety of embryonic tissues, but its expression in adult arteries is co-incident with sites of vascular disease. TnC expression has been linked to the development and complications of intimal hyperplasia, pulmonary artery hypertension, atherosclerosis, myocardial infarction, and heart failure. This review identifies the growing collection of evidence linking TnC with cardiovascular disease development. The transient upregulation of this extracellular matrix protein at sites of vascular disease could provide a means to target TnC in the development of diagnostics and new therapies. Studies in TnC-deficient mice have implicated this protein in the development of intimal hyperplasia. Further animal and human studies are required to thoroughly assess the role of TnC in some of the other pathologies it has been linked with, such as atherosclerosis and pulmonary hypertension. Large population studies are also warranted to clarify the diagnostic value of this extracellular matrix protein in cardiovascular disease, for example by targeting its expression using radiolabelled antibodies or measuring circulating concentrations of TnC.
Introduction
Tenascin C (TnC) is a large extracellular matrix glycoprotein and was the first member identified of a family of four structurally similar proteins, including tenascin R, W and X. 1 -3 During early development, TnC is transiently expressed at a number of sites throughout the embryo, such as neural crest, central nervous system, lungs, and cardiovascular system. 1 Despite this implied function during embryogenesis, knockout mice models of TnC grow to maturity without any overt signs of abnormalities. 4 In normal adult tissue, only low levels of TnC are found. Higher levels of TnC expression have been reported in areas of wound healing, cancer development, and cardiovascular disease. 1 Given this localization of TnC to sites of pathology, there has been increasing interest in assessing the role of this glycoprotein in disease development and targeting the protein in both diagnosis and therapy for a variety of pathologies. 1 In this review, we summarize previous studies which have examined the expression and potential influence of TnC in cardiovascular disease.
Structure of TnC
The structure of TnC is relevant to its functions in health and disease and has been described in detail in previous reviews. 1 -3 TnC polypeptides are made up of a number of domains ( Figure 1A ) and include:
(a) An amino-terminal Tn assembly domain (TA) which is responsible for interactions between TnC polypeptides important in assembly of the multimeric protein; (b) A contiguous group of repeats of epidermal growth factor-like domains; (c) A series of fibronectin type III domains; (d) A distal globular fibrinogen-homology domain.
While TnC is encoded by a single gene located at 9q33 in man, alternative splicing of mRNA can result in a large number of different isoforms with between 1 and 6 extra fibronectin type III domains (A1, A2, A4, B, C, and D) ( Figure 1B) . Ultimately, six TnC polypeptides can be assembled into a six armed structure referred to as a hexabrachion via interaction at the TA domains. This form of TnC has been identified within the extracellular matrix such as that present during embryonic development. The relative expression of different forms of TnC present in diseased adult tissue and circulating in the blood has been poorly described.
TnC interactions and signalling pathways
Associated with its complex structure, TnC has the capacity to interact with several different cell surface receptors. Different parts of the TnC protein have been ascribed to binding different receptors. 1, 3 The epidermal growth factor-like domains can bind the epidermal growth factor receptor. The third fibronectin type III repeat binds avb3 and other integrins promoting adhesion. The variable spliced A-D fibronectin type III repeats bind annexin II thereby inhibiting adhesion. The variable splice region has also been shown to interact with F3/ contactin and a7b1 integrin. 3 Thus, different isoforms of TnC would be expected to have different functional effects, although this has not been clearly defined.
4.
In vitro studies assessing the determinants of TnC production and the interaction of TnC with vascular cells
The determinants of TnC expression have been examined in vitro in a variety of cells relevant to vascular disease, including vascular smooth muscle cells (VSMCs), endothelial cells, and monocyte-macrophages ( Table 1) . 5 -26 Overall, a range of factors implicated in cardiovascular disease, including cytokines, angiotensin II, and haemodynamic forces appear to be able to upregulate TnC expression in vitro. A number of medications have been reported to reduce TnC expression, including steroids, cilostazol, and non-steroidal anti-inflammatory drugs. 12, 15, 24 Identified intra-cellular regulators of TnC expression in vascular cells include homeobox transcription factor Prx1, Rho, and extracellular signal-regulated kinases. 11,18 -20 TnC expression has been shown to be under post-transcription control in non-vascular sites, such as within breast cancer metastases, where micro RNAs, including miR-355, have been shown to control TnC expression. 27 The actions of TnC have also been examined in vitro employing a range of cell types and TnC fragments ( Table 2) . 10,20,21,28 -50 TnC has been reported to promote angiogenesis and release of pro-inflammatory cytokines and MMPs. TnC has also been reported to inhibit T cell proliferation and activation in vitro. The effects of TnC within in vitro studies seem to vary according to the fragment of TnC employed and the cell type studied. The region of TnC which contains the fibronectin type III repeats, and which varies by isoform type (Figure 1 ), appears to control the ability of TnC to influence cell adhesion. 21, 40, 42, 46, 47 The epidermal growth factor-like domains of TnC have been suggested to control cell survival, while the distal globular fibrinogen-homology domain has been associated with stimulating cytokine production. 31, 51 5. Animal studies examining the expression and role of TnC in cardiovascular disease
The association of TnC with a range of cardiovascular pathologies has been examined in murine, lapine, porcine, bovine, and canine models of human cardiovascular diseases ( Tables 3-5) . 5,10,15,17,21,23,33,34,52 -71 The most common pathology studied has been intimal hyperplasia (Table 3) . 5,15,23,33,52 -58 TnC has been implicated in the development of intimal hyperplasia following angioplasty, stenting, arteriotomy, and bypass grafting in animal species as diverse as mice and pigs. 5,15,23,33,52 -58 TnC is expressed very rapidly following arterial injury in these models and its expression is reduced in situations where intimal hyperplasia is inhibited, such as prostaglandin E2 deficiency or treatment with a nitric oxide donor. 5, 58 Importantly, intimal hyperplasia has been reported to be reduced in two distinct mouse models of TnC deficiency, suggesting that this protein plays 98 The N-terminal domain is called the tenascin assembly domain (TA) and is involved in the formation of the quarternary hexabrachion structure. Within this region, there is a heat shock protein 33 motif probably responsible for TnC aggregation within the cell. 98 The next region includes 14 epidermal growth factor (EGF) like repeats which are quite consistent. The EGF-like repeat domain modulates cell adhesion and cell motility. 99 This region is considered to be counter adhesive for fibroblasts, neurons, and glia and may be involved in neuronal migration and axon path finding during development. 1 The following region contains the fibronectin (FN Studies in rodent, pig, and dog models of myocardial infarction have demonstrated that TnC is highly expressed from approximately day 1 to day 14 within the peri-infarct area. This has promoted interest in developing diagnostic aids that incorporate antibodies targeting this protein (Table 4) . 34,59 -64 The TnC expression has been linked to an exaggerated repair process after myocardial infarction with reduced interstitial fibrosis reported in TnC-deficient mice following coronary artery ligation. 59 TnC-deficient mice also have reduced myocardial stiffness on echocardiography after myocardial infarction. 59 TnC expression has also been positively linked to a range of other cardiovascular pathologies, including atherosclerosis, pulmonary artery hypertension, neovascularization, the peri-infarct repair process following stroke, angiotensin II-induced cardiac fibrosis, vasospasm following subarachnoid haemorrhage, and vascular calcification ( Table 5) . 10,17,21,23,59,65 -71 In keeping with in vitro findings noted earlier, neovascularization has been reported to be reduced in TnC-deficient mice, suggesting TnC promotes angiogenesis. 10 To summarize, studies in animal models most clearly support a role of TnC in intimal hyperplasia, although the exact mechanisms for this are unclear. Although TnC is associated with many other cardiovascular pathologies in animal models, clear evidence that links TnC with their development and outcomes is currently lacking.
Human studies examining the expression of TnC in relation to cardiovascular disease
A large number of studies have examined the expression of TnC in biopsies removed from patients with a variety of cardiac and other cardiovascular diseases (Tables 6 and 7) . TnC has been reported to be increased in patients with a range of cardiac problems, including acute myocardial infarction, pulmonary thromboembolism, pulmonary artery hypertension, left ventricular hypertrophy, and dilated cardiomyopathy compared with controls in cross-sectional studies ( Table 8) . 85 -91 Overall, the number of subjects included in these studies has been small, however, with a total of only 408 cases and 136 controls included in the independent crosssectional studies identified in this systematic review ( Table 8) .
The TnC isoform measured in these studies has varied but in most instances appears to have been the high molecular weight isoform containing the fibronectin type III C domain. Assays have been performed using commercial enzyme-linked immunoassays from two different companies. TnC, tenascin C; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; TGF, transforming growth factor; TNF, tumour necrosis factor; IL, interleukin; TnfnIII, tenascin C fibronectin type III repeat domain; VSMC, vascular smooth muscle cells.
disease but also related to specific clinical findings, imaging results, and subsequent outcomes in these patients. 87 -93 Serum TnC concentration has, for example, been correlated with New York Heart Association functional class and left ventricular ejection fraction in patients with heart failure. 88, 90 Serum TnC has also been reported to predict the prospective incidence of cardiovascular events in patients who have recently had a myocardial infarction, have heart failure or chronic kidney disease. 89, 92, 93 The reported area under the curves of receiver operator characteristic curves in these studies were between 0.77 and 0.79. 89, 93 These findings suggest that most likely serum TnC would need to be combined with other clinical and biomarker predictors to be of clinical value. In summary, data from human association studies fit with animal data linking TnC with a range of cardiovascular diseases, although the therapeutic and diagnostic value has been little examined. with gammaglutamyl transferase levels in 1955 hypertensive subjects. 96 Otherwise, there has only been a single published study specifically examining the association of genetic polymorphisms in TNC and cardiovascular disease, and this did not include rs17819305. 97 Minear et al. 97 genotyped a total of 35 single nucleotide polymorphisms (SNPs), including 21 haplotype tagging SNPs, in a range of subjects that had been assessed for different measures of atherosclerosis. The subjects examined included 205 heart transplant donors who had provided ascending aortic samples; 1325 patients who had undergone coronary angiography to assess severity of coronary atherosclerosis; and 879 families with a history of coronary heart disease. Three SNPs, rs3789875, rs12347433, and rs4552883, representing a block of linkage disequilibrium were significantly associated with aortic atherosclerosis plaque presence in the heart transplant donors and coronary heart disease in the two large subject groups. One of these SNPs, rs12347433, is a synonymous polymorphism causing a change in the mRNA without affecting the amino acid sequence of the TnC protein. This type of synonymous polymorphism has been suggested to alter mRNA function or stability which could alter translation and thus TnC expression. However, none of these SNPs was associated with TnC expression measured by microarrays within the 104 patients in which aortic RNA was available, suggesting these polymorphisms may be acting via mechanisms unrelated to aortic concentration of TnC mRNA.
Association of genetic polymorphisms in the gene encoding TnC and cardiovascular disease

Summary and future directions
A large number of studies suggest that TnC is transiently expressed in association with a range of cardiovascular diseases in both animal models and patients. Whether this association is part of the repair process or pathological is not completely resolved in most instances. Studies from TnC-deficient mice suggest that in the case of intimal hyperplasia (perhaps the best-studied example) that TnC plays a pathological role, most likely because of the ability of TnC to promote MMP production, and VSMC proliferation and chemotaxis. 20, 34, 37, 44, 52, 53 The role of TnC in atherosclerosis is less clear cut, although a number of findings (such as its expression at sites of plaque rupture, its involvement in neovascularization, and its ability to influence VSMC phenotype and pro-inflammatory cytokine/MMP production) would suggest that it may play a role in promoting the development and complications of this pathology. 10 In this study, the lower molecular weight FNIIIB domain containing TnC isoform was measured while in other studies the higher molecular weight FNIIIC domain containing TnC isoform appears to have been measured. TnC, tenascin C; AUC, area under the curve; ROC, receiver operator characteristic; LV, left ventricular; NYHA, New York Heart Association; MACE, major adverse cardiovascular events; CRT, cardiac resynchronization therapy.
